Luigi Bolondi

List of Publications by Citations

86 papers	19,281 citations	43 h-index	86 g-index
86 ext. papers	22,225 ext. citations	6.9 avg, IF	6.05 L-index

#	Paper	IF	Citations
86	Sorafenib in advanced hepatocellular carcinoma. *New England Journal of Medicine*, **2008**, 359, 378-90	59.2	9089
85	Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma. *New England Journal of Medicine*, **2018**, 379, 54-63	59.2	1015
84	Cyclin G1 is a target of miR-122a, a microRNA frequently down-regulated in human hepatocellular carcinoma. *Cancer Research*, **2007**, 67, 6092-9	10.1	695
83	Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals. *Journal of Hepatology*, **2016**, 65, 727-733	13.4	612
82	Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial. *Journal of Hepatology*, **2012**, 57, 821-9	13.4	589
81	Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. *Lancet Oncology, The*, **2015**, 16, 1344-54	21.7	553
80	The safety of Sonovue in abdominal applications: retrospective analysis of 23188 investigations. *Ultrasound in Medicine and Biology*, **2006**, 32, 1369-75	3.5	526
79	Heterogeneity of patients with intermediate (BCLC B) Hepatocellular Carcinoma: proposal for a subclassification to facilitate treatment decisions. *Seminars in Liver Disease*, **2012**, 32, 348-59	7.3	387
78	Characterization of small nodules in cirrhosis by assessment of vascularity: the problem of hypovascular hepatocellular carcinoma. *Hepatology*, **2005**, 42, 27-34	11.2	356
77	Percutaneous ethanol injection in the treatment of hepatocellular carcinoma in cirrhosis. A study on 207 patients. *Cancer*, **1992**, 69, 925-9	6.4	356
76	MiR-199a-3p regulates mTOR and c-Met to influence the doxorubicin sensitivity of human hepatocarcinoma cells. *Cancer Research*, **2010**, 70, 5184-93	10.1	347
75	MiR-122/cyclin G1 interaction modulates p53 activity and affects doxorubicin sensitivity of human hepatocarcinoma cells. *Cancer Research*, **2009**, 69, 5761-7	10.1	346
74	Natural history of small untreated hepatocellular carcinoma in cirrhosis: a multivariate analysis of prognostic factors of tumor growth rate and patient survival. *Hepatology*, **1992**, 16, 132-7	11.2	342
73	MicroRNA-221 targets Bmf in hepatocellular carcinoma and correlates with tumor multifocality. *Clinical Cancer Research*, **2009**, 15, 5073-81	12.9	267
72	Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study. *Lancet Oncology, The*, **2018**, 19, 682-693	21.7	216
71	MicroRNA involvement in hepatocellular carcinoma. *Journal of Cellular and Molecular Medicine*, **2008**, 12, 2189-204	5.6	212
70	Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: multicentre, open-label, phase II safety study. *European Journal of Cancer*, **2013**, 49, 3412-9	7.5	178

69	Updated use of TACE for hepatocellular carcinoma treatment: How and when to use it based on clinical evidence. *Cancer Treatment Reviews*, **2019**, 72, 28-36	14.4	163
68	In hepatocellular carcinoma miR-519d is up-regulated by p53 and DNA hypomethylation and targets CDKN1A/p21, PTEN, AKT3 and TIMP2. *Journal of Pathology*, **2012**, 227, 275-85	9.4	155
67	Screening for hepatocellular carcinoma in cirrhosis. *Journal of Hepatology*, **2003**, 39, 1076-84	13.4	153
66	Contribution of the hepatobiliary phase of Gd-EOB-DTPA-enhanced MRI to Dynamic MRI in the detection of hypovascular small (≤ 2 cm) HCC in cirrhosis. *European Radiology*, **2011**, 21, 1233-42	8	152
65	The impact of vascular and nonvascular findings on the noninvasive diagnosis of small hepatocellular carcinoma based on the EASL and AASLD criteria. *American Journal of Gastroenterology*, **2010**, 105, 599-609	0.7	151
64	Liver tumorigenicity promoted by microRNA-221 in a mouse transgenic model. *Hepatology*, **2012**, 56, 1025-33	11.2	132
63	Position paper of the Italian Association for the Study of the Liver (AISF): the multidisciplinary clinical approach to hepatocellular carcinoma. *Digestive and Liver Disease*, **2013**, 45, 712-23	3.3	128
62	The treatment of intermediate stage tumours beyond TACE: From surgery to systemic therapy. *Journal of Hepatology*, **2017**, 67, 173-183	13.4	106
61	Usefulness of contrast-enhanced perfusional sonography in the assessment of hepatocellular carcinoma hypervascular at spiral computed tomography. *Journal of Hepatology*, **2004**, 41, 421-6	13.4	104
60	Circulating microRNAs, miR-939, miR-595, miR-519d and miR-494, Identify Cirrhotic Patients with HCC. *PLoS ONE*, **2015**, 10, e0141448	3.7	94
59	Contrast-enhanced ultrasound in the diagnosis of hepatocellular carcinoma. *Journal of Hepatology*, **2008**, 48, 848-57	13.4	93
58	VEGF and VEGFR genotyping in the prediction of clinical outcome for HCC patients receiving sorafenib: the ALICE-1 study. *International Journal of Cancer*, **2014**, 135, 1247-56	7.5	88
57	Non-transplant therapies for patients with hepatocellular carcinoma and Child-Pugh-Turcotte class B cirrhosis. *Lancet Oncology, The*, **2017**, 18, e101-e112	21.7	87
56	Characterization of focal liver lesions with contrast-enhanced ultrasound. *Ultrasound in Medicine and Biology*, **2010**, 36, 531-50	3.5	83
55	Yttrium-90 radioembolization vs sorafenib for intermediate-locally advanced hepatocellular carcinoma: a cohort study with propensity score analysis. *Liver International*, **2015**, 35, 1036-47	7.9	81
54	Hepatocellular carcinoma: epidemiology and clinical aspects. *Molecular Aspects of Medicine*, **2008**, 29, 130-43	16.7	78
53	Criteria for diagnosing benign portal vein thrombosis in the assessment of patients with cirrhosis and hepatocellular carcinoma for liver transplantation. *Liver Transplantation*, **2010**, 16, 658-67	4.5	70
52	Conditional survival after hepatic resection for hepatocellular carcinoma in cirrhotic patients. *Clinical Cancer Research*, **2012**, 18, 4397-405	12.9	63

51	Circulating miR-106b-3p, miR-101-3p and miR-1246 as diagnostic biomarkers of hepatocellular carcinoma. *Oncotarget*, **2018**, 9, 15350-15364	3.3	59
50	Prognostic significance of adverse events in patients with hepatocellular carcinoma treated with sorafenib. *Therapeutic Advances in Gastroenterology*, **2016**, 9, 240-9	4.7	56
49	Consensus on the current use of sorafenib for the treatment of hepatocellular carcinoma. *European Journal of Gastroenterology and Hepatology*, **2010**, 22, 391-8	2.2	56
48	The epigenetically regulated miR-494 associates with stem-cell phenotype and induces sorafenib resistance in hepatocellular carcinoma. *Cell Death and Disease*, **2018**, 9, 4	9.8	48
47	Metronomic capecitabine as second-line treatment in hepatocellular carcinoma after sorafenib failure. *Digestive and Liver Disease*, **2015**, 47, 518-22	3.3	46
46	The intermediate hepatocellular carcinoma stage: Should treatment be expanded?. *Digestive and Liver Disease*, **2010**, 42 Suppl 3, S258-63	3.3	46
45	Use of VEGFR-2 targeted ultrasound contrast agent for the early evaluation of response to sorafenib in a mouse model of hepatocellular carcinoma. *Molecular Imaging and Biology*, **2015**, 17, 29-37	3.8	43
44	Adherence to AASLD guidelines for the treatment of hepatocellular carcinoma in clinical practice: experience of the Bologna Liver Oncology Group. *Digestive and Liver Disease*, **2014**, 46, 549-55	3.3	43
43	Real time contrast enhanced ultrasonography in detection of liver metastases from gastrointestinal cancer. *BMC Cancer*, **2007**, 7, 171	4.8	41
42	Notch3 inhibition enhances sorafenib cytotoxic efficacy by promoting GSK3b phosphorylation and p21 down-regulation in hepatocellular carcinoma. *Oncotarget*, **2013**, 4, 1618-31	3.3	40
41	Tumor doubling time predicts recurrence after surgery and describes the histological pattern of hepatocellular carcinoma on cirrhosis. *Journal of Hepatology*, **2005**, 43, 310-6	13.4	38
40	Suppression of p53 by Notch3 is mediated by Cyclin G1 and sustained by MDM2 and miR-221 axis in hepatocellular carcinoma. *Oncotarget*, **2014**, 5, 10607-20	3.3	37
39	p53/mdm2 feedback loop sustains miR-221 expression and dictates the response to anticancer treatments in hepatocellular carcinoma. *Molecular Cancer Research*, **2014**, 12, 203-16	6.6	36
38	Immune inflammation indicators and ALBI score to predict liver cancer in HCV-patients treated with direct-acting antivirals. *Digestive and Liver Disease*, **2019**, 51, 681-688	3.3	36
37	Assessment of vascular patterns of small liver mass lesions: value and limitation of the different Doppler ultrasound modalities. *American Journal of Gastroenterology*, **2000**, 95, 3537-46	0.7	35
36	Over-expression of the miR-483-3p overcomes the miR-145/TP53 pro-apoptotic loop in hepatocellular carcinoma. *Oncotarget*, **2016**, 7, 31361-71	3.3	33
35	LncRNAs as novel players in hepatocellular carcinoma recurrence. *Oncotarget*, **2018**, 9, 35085-35099	3.3	31
34	State of the art: hepatocellular carcinoma. *Future Oncology*, **2014**, 10, 1-6	3.6	29

33	TACE performed in patients with a single nodule of hepatocellular carcinoma. *BMC Cancer*, **2014**, 14, 601	4.8	28
32	Design, synthesis and biological evaluation of pyrazole derivatives as potential multi-kinase inhibitors in hepatocellular carcinoma. *European Journal of Medicinal Chemistry*, **2012**, 48, 391-401	6.8	28
31	MiR-30e-3p Influences Tumor Phenotype through / Axis and Predicts Sorafenib Resistance in Hepatocellular Carcinoma. *Cancer Research*, **2020**, 80, 1720-1734	10.1	27
30	MiR-122 Targets SerpinB3 and Is Involved in Sorafenib Resistance in Hepatocellular Carcinoma. *Journal of Clinical Medicine*, **2019**, 8,	5.1	26
29	Treatment of hepatocellular carcinoma in Child-Pugh B patients. *Digestive and Liver Disease*, **2013**, 45, 852-8	3.3	25
28	TP53/MicroRNA Interplay in Hepatocellular Carcinoma. *International Journal of Molecular Sciences*, **2016**, 17,	6.3	22
27	Molecular and proteomic insight into Notch1 characterization in hepatocellular carcinoma. *Oncotarget*, **2016**, 7, 39609-39626	3.3	21
26	Second-line cabozantinib after sorafenib treatment for advanced hepatocellular carcinoma: a subgroup analysis of the phase 3 CELESTIAL trial. *ESMO Open*, **2020**, 5,	6	21
25	From liver cirrhosis to HCC. *Internal and Emergency Medicine*, **2011**, 6 Suppl 1, 93-8	3.7	20
24	Diagnostic and prognostic value of DNA ploidy and cell nuclearity in ultrasound-guided liver biopsies. *Cancer*, **1994**, 74, 1713-9	6.4	19
23	Refining sorafenib therapy: lessons from clinical practice. *Future Oncology*, **2015**, 11, 449-65	3.6	17
22	Serum albumin-bound proteomic signature for early detection and staging of hepatocarcinoma: sample variability and data classification. *Clinical Chemistry and Laboratory Medicine*, **2010**, 48, 1319-26	5.9	17
21	In hepatocellular carcinoma AgNOR protein expression correlates with tumour mass doubling time. *Journal of Hepatology*, **1996**, 24, 60-5	13.4	17
20	MiR-199-3p replacement affects E-cadherin expression through Notch1 targeting in hepatocellular carcinoma. *Acta Histochemica*, **2018**, 120, 95-102	2	16
19	Radiologic criteria of response to systemic treatments for hepatocellular carcinoma. *Hepatic Oncology*, **2017**, 4, 129-137	4	15
18	Recent advances in the diagnosis of hepatocellular carcinoma. *Hepatology Research*, **2007**, 37 Suppl 2, S178-92	5.1	15
17	Efficacy and Safety of Systemic Therapies for Advanced Hepatocellular Carcinoma: A Network Meta-Analysis of Phase III Trials. *Liver Cancer*, **2017**, 6, 337-348	9.1	13
16	miRNA Signature of Hepatocellular Carcinoma Vascularization: How the Controls Can Influence the Signature. *Digestive Diseases and Sciences*, **2017**, 62, 2397-2407	4	12

15	Liver metastases from rectal carcinoma: disease progression during chemotherapy despite loss of arterial-phase hypervascularity on real-time contrast-enhanced harmonic sonography at low acoustic energy. *Journal of Clinical Ultrasound*, **2003**, 31, 387-91	1	12
14	Durable Complete Response of Hepatocellular Carcinoma after Metronomic Capecitabine. *Tumori*, **2010**, 96, 1028-1030	1.7	11
13	Vidatox 30 CH has tumor activating effect in hepatocellular carcinoma. *Scientific Reports*, **2017**, 7, 44685	4.9	10
12	Contrast-enhanced ultrasonography to diagnose complicated acute cholecystitis. *Internal and Emergency Medicine*, **2016**, 11, 19-30	3.7	9
11	Cost analysis of recall strategies for non-invasive diagnosis of small hepatocellular carcinoma. *Digestive and Liver Disease*, **2010**, 42, 729-34	3.3	9
10	A phase I study of continuous hepatic arterial infusion of Irinotecan in patients with locally advanced hepatocellular carcinoma. *Digestive and Liver Disease*, **2011**, 43, 1015-21	3.3	8
9	Enzymatic cytochemistry, DNA ploidy and AgNOR quantitation in hepatocellular nodules of uncertain malignant potential in liver cirrhosis. *Digestive Diseases and Sciences*, **1996**, 41, 800-8	4	8
8	Pathobiological and Radiological Approach For Hepatocellular Carcinoma Subclassification. *Scientific Reports*, **2019**, 9, 14749	4.9	7
7	Evaluation of the impact of transient interruption of antiangiogenic treatment using ultrasound-based techniques in a murine model of hepatocellular carcinoma. *BMC Cancer*, **2014**, 14, 403	4.8	7
6	Comparative analysis of current guidelines for the treatment of hepatocellular carcinoma. *Hepatic Oncology*, **2016**, 3, 119-136	4	7
5	DAAs for HCV and risk of hepatocellular carcinoma: current standpoint. *The Lancet Gastroenterology and Hepatology*, **2018**, 3, 736-738	18.8	5
4	From large to small: the immunohistochemical panel in the diagnosis of early hepatocellular carcinoma. *Histopathology*, **2018**, 72, 414-422	7.3	4
3	Contrast-enhanced ultrasound in liver cancer. *Hepatic Oncology*, **2015**, 2, 51-62	4	3
2	Medical treatment of hepatocellular carcinoma. *Mediterranean Journal of Hematology and Infectious Diseases*, **2009**, 1, e2009021	3.2	2
1	Imaging of the Liver500-548		